Valuation: SurModics

Market Cap 43Cr 37Cr 34Cr 32Cr 61Cr 4.08TCr 62Cr 413.5Cr 160.15Cr 1.99TCr 160.4Cr 156.96Cr 6.89TCr P/E 2023
-292x
P/E 2024 -47.3x
Enterprise Value 42Cr 37Cr 34Cr 32Cr 60Cr 4.01TCr 61Cr 406.86Cr 157.57Cr 1.95TCr 157.83Cr 154.44Cr 6.78TCr EV / Sales 2023
3.33x
EV / Sales 2024 4.33x
Free-Float
99.63%
Yield 2023 *
-
Yield 2024 -
1 year 25.87
Extreme 25.87
43
3 years 25.17
Extreme 25.17
43
5 years 16
Extreme 16
62.27
10 years 16
Extreme 16
82.35
Manager TitleAgeSince
Chief Executive Officer 67 19/11/2025
Director of Finance/CFO 53 19/11/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 19/11/2025
Director/Board Member 53 19/11/2025
Date Insider Type Main position Quantity % Market Cap.
19/11Issuer sale

Director

62,052 0.4340%
19/11Issuer sale

Director

51,877 0.3628%
19/11Issuer sale

General Counsel

1,08,900 0.7617%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-.--%+46.79%+37.27% 61Cr
+3.49%+5.43%-29.99%-12.49% 16TCr
+5.04%+3.82%-6.26%-5.57% 10TCr
+2.80%+4.23%+0.40%+54.09% 5.61TCr
-1.22%-2.88%+53.69%+49.87% 5.34TCr
+3.39%+6.98%-11.03%-40.12% 4.21TCr
+3.50%+19.81% - - 3.53TCr
+3.47%+2.15%-14.75%-44.56% 2.66TCr
+0.20%+7.44%+64.44%-4.37% 2.58TCr
+2.78%+5.32%-10.08%-3.01% 2.07TCr
Average +1.46%+2.80%+10.36%+3.45% 5.22TCr
Weighted average by Cap. +0.77%+2.00%-3.98%+0.20%

Financials

2023 2024
Net sales 13Cr 12Cr 11Cr 9.93Cr 19Cr 1.26TCr 19Cr 128.29Cr 50Cr 616.09Cr 50Cr 49Cr 2.14TCr 13Cr 11Cr 10Cr 9.45Cr 18Cr 1.2TCr 18Cr 121.99Cr 47Cr 585.86Cr 47Cr 46Cr 2.03TCr
Net income -15.36L -13.44L -12.35L -11.51L -21.79L -15Cr -22.2L -1.49Cr -57.56L -7.14Cr -57.65L -56.42L -25Cr -1.15Cr -1.01Cr -92.77L -86.48L -1.64Cr -110.09Cr -1.67Cr -11Cr -4.33Cr -54Cr -4.33Cr -4.24Cr -186.04Cr
Net Debt -1.21Cr -1.06Cr -97.26L -90.67L -1.72Cr -115.42Cr -1.75Cr -12Cr -4.53Cr -56Cr -4.54Cr -4.44Cr -195.05Cr -68.7L -60.1L -55.22L -51.47L -97.44L -66Cr -99.29L -6.65Cr -2.57Cr -32Cr -2.58Cr -2.52Cr -110.74Cr
Logo SurModics
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Employees
389
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SRDX Stock